| Expression pattern: |
DN |
| Associated gene: |
AGO2, EIF4A3, ELAVL1 (HuR), EWSR1, FMR1 (FMRP), FUS, IGF2BP1, IGF2BP2, IGF2BP3, LIN28A, LIN28B, PTBP1, U2AF2 (U2AF) |
| Associated microRNA: |
- |
| Biological function: |
Acts as a risk biomarker candidate distinguishing TNBC from non-cancer controls; may mediate gene regulation via interactions with RNA-binding proteins. |
| Molecular mechanism: |
Predicted circRNA-RBP interaction network (CLIP-seq-based) with enrichment in transcriptional/post-transcriptional gene regulation pathways. |
| Biological pathway or process: |
other pathway/process (other) |
| Detected method: |
Q
S
|
| Validation methods: |
RNA-seq; RT-qPCR; Clinical Sample Validation; ROC Analysis; Bioinformatics Analysis |
| Clinical significance: |
hsa_circ_0072309 expression distinguished TNBC patients from patients without cancer with AUC of 0.78 (FFPE) and 0.81 (frozen tissue), suggesting a potential risk biomarker. |
| Description: |
hsa_circ_0072309 is consistently down-regulated in TNBC across RNA-seq and RT-qPCR validation cohorts and can discriminate TNBC from non-cancer breast samples (AUC ~0.78-0.81). Its putative role is linked to circRNA-RBP interactions, with predicted RBPs enriched in cancer-related gene regulation pathways. |
| Confidence score: |
0.5047 |